The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia
Status:
Unknown status
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this pilot study is to investigate whether some patients who were started on a
2G-TKI as first-line treatment can be safely switched to imatinib, a first-generation TKI,
while maintaining or even deepening the molecular response as a cost-effective treatment.
Eligible patients will be switched to imatinib 400mg daily, with regular molecular
monitoring.